Maximising the accessibility of research results in the fight against Covid-19

Fields marked with * are mandatory.

The <u>COVID-19 Research MANIFESTO</u> offers the opportunity for public and private stakeholders benefitting from EU funding, other research funders and prominent individuals and institutions to express their support and endorse the manifesto.

Maximising the accessibility of research results in the fight against Covid-19

Considering the unprecedented, extraordinary challenges posed by the outbreak of the COVID-19 pandemic.

Encouraged by the broad public recognition of the important role of research and innovation in ending the COVID-19 pandemic.

Recalling the World Health Assembly resolution on COVID-19[1] and EU Strategy for COVID-19 vaccines[2] supporting the voluntary pooling and licensing of intellectual property related to Covid-19 therapeutics and vaccines, to promote equitable global access as well as a fair return on investments

Fully aware of our responsibility as researchers and innovators to find innovative solutions.

Bearing in mind the urgent need to valorise research results for the benefit of all.

We agree and endorse the principles below when dealing to research results steaming from EU funded research grants related to COVID-19 on

prevention, testing, treatment and vaccination:

- Make the generated results, whether tangible or intangible, public and accessible without delay, for instance on the Horizon Results Platform, on an existing IP sharing platform, or through an existing patent pool;
- Make scientific papers and research data available in open access without delay and following the FAIR principles via preprint servers or public repositories, with rights for others to build upon the publications and data and with access to the tools needed for their validation. Specifically for COVID-19 research data, make them available through the European COVID-19 Data Platform;
- Where possible, grant limited time[3], non-exclusive royalty free licences for the intellectual property. These non-exclusive royalty free licenses will be given in exchange for the licensees' commitment to rapidly and broadly distribute the resulting products and services under fair and reasonable conditions to prevent, diagnose, treat and contain Covid-19;

[1] https://apps.who.int/gb/ebwha/pdf_files/WHA73/A73_R1-en.pdf
[2] https://ec.europa.eu/info/sites/info/files/communication-eu-strategy-vaccines-covid19_en.pdf
[3] until 1 year after the WHO declaration that Covid-19 is not anymore a 'Public Health Emergency of International Concern' but in any event not beyond 1 January 2022 unless otherwise extended by the beneficiary

* I would like to endorse the manifesto

 $^{\odot}$ as a person $^{\odot}$ as an organisation

* First name

Text of 2 to 64 characters will be accepted

Núria

* Family name

Text of 2 to 64 characters will be accepted

Romero

* Email address

Text of 5 to 64 characters will be accepted

info@asphalion.com

Organisation

Asphalion

Your position in the organisation

Managing Director

Country

- AF Afghanistan
- 🔘 AL Albania
- DZ Algeria
- AD Andorra
- AO Angola
- AG Antigua and Barbuda
- AR Argentina
- AM Armenia
- 🔘 AU Australia
- 🔘 AT Austria
- AZ Azerbaijan
- 🔘 BS Bahamas
- 🔘 BH Bahrain
- BD Bangladesh
- BB Barbados
- BY Belarus
- BE Belgium
- BZ Belize
- BJ Benin
- 🔘 BT Bhutan
- 🔘 BO Bolivia
- BA Bosnia and Herzegovina
- BW Botswana
- 🔘 BR Brazil
- BN Brunei Darussalam
- 🔘 BG Bulgaria
- 🔘 BF Burkina Faso
- 🔘 BI Burundi
- CV Cabo Verde
- KH Cambodia
- CM Cameroon
- 🔘 CA Canada

- CF Central African Republic
- TD Chad
- CL Chile
- CN China
- 🔘 CO Colombia
- KM Comoros
- CG Congo
- 🔘 CR Costa Rica
- HR Croatia
- 🔘 CU Cuba
- OY Cyprus
- CZ Czechia
- CI C&te D'Ivoire
- CD Democratic Republic of the Congo
- DK Denmark
- 🔘 DJ Djibouti
- OM Dominica
- DO Dominican Republic
- EC Ecuador
- EG Egypt
- SV El Salvador
- GQ Equatorial Guinea
- 🔘 ER Eritrea
- 🔘 EE Estonia
- SZ Eswatini
- 🔘 ET Ethiopia
- 🔘 FJ Fiji
- FI Finland
- FR France
- GA Gabon
- 🔘 GM Gambia
- 🔘 GE Georgia
- DE Germany
- 🔘 GH Ghana
- GR Greece
- 🔘 GD Grenada
- 🔘 GT Guatemala
- GN Guinea
- 🔘 GW Guinea Bissau
- 🔘 GY Guyana
- 🔘 HT Haiti
- HN Honduras
- HU Hungary
- IS Iceland
- 🔘 IN India
- 🔘 ID Indonesia
- 🔘 IR Iran

- 🔘 IQ Iraq
- IE Ireland
- IL Israel
- IT Italy
- 🔘 JM Jamaica
- 🔘 JP Japan
- 🔘 JO Jordan
- 🔘 KZ Kazakhstan
- 🔘 KE Kenya
- 🔘 KI Kiribati
- 🔘 KW Kuwait
- KG Kyrgyzstan
- 🔘 LA Laos
- 🔘 LV Latvia
- 🔘 LB Lebanon
- LS Lesotho
- 🔘 LR Liberia
- 🔘 LY Libya
- LI Liechtenstein
- 🔘 LT Lithuania
- LU Luxembourg
- MG Madagascar
- 🔘 MW Malawi
- 🔘 MY Malaysia
- MV Maldives
- 🔘 ML Mali
- 🔘 MT Malta
- MH Marshall Islands
- 🔘 MR Mauritania
- MU Mauritius
- MX Mexico
- FM Micronesia
- MC Monaco
- MN Mongolia
- ME Montenegro
- MA Morocco
- MZ Mozambique
- MM Myanmar
- 🔍 NA Namibia
- NR Nauru
- NP Nepal
- NL Netherlands
- NZ New Zealand
- NI Nicaragua
- NE Niger
- 🔘 NG Nigeria
- KP North Korea

- MK North Macedonia
- NO Norway
- OM Oman
- PK Pakistan
- 🔘 PW Palau
- 🔘 PA Panama
- PG Papua New Guinea
- PY Paraguay
- 🔘 PE Peru
- PH Philippines
- PL Poland
- PT Portugal
- 🔘 QA Qatar
- MD Republic of Moldova
- 🔘 RO Romania
- RU Russian Federation
- 🔘 RW Rwanda
- KN Saint Kitts and Nevis
- LC Saint Lucia
- VC Saint Vincent and the Grenadines
- 🔘 WS Samoa
- 🔘 SM San Marino
- ST Sao Tome and Principe
- 🔘 SA Saudi Arabia
- SN Senegal
- RS Serbia
- SC Seychelles
- SL Sierra Leone
- SG Singapore
- SK Slovakia
- SI Slovenia
- SB Solomon Islands
- 🔘 SO Somalia
- ZA South Africa
- KR South Korea
- SS South Sudan
- ES Spain
- 🔘 LK Sri Lanka
- 🔘 SD Sudan
- SR Suriname
- SE Sweden
- CH Switzerland
- SY Syrian Arab Republic
- 🔘 TJ Tajikistan
- 🔘 TZ Tanzania
- 🔘 TH Thailand
- TL Timor-Leste

- 🔘 TG Togo
- 🔘 TO Tonga
- TT Trinidad and Tobago
- 🔘 TN Tunisia
- TR Turkey
- TM Turkmenistan
- 🔘 TV Tuvalu
- 🔘 UG Uganda
- 🔘 UA Ukraine
- AE United Arab Emirates
- GB United Kingdom
- US United States of America
- UY Uruguay
- UZ Uzbekistan
- 🔘 VU Vanuatu
- VE Venezuela
- VN Viet Nam
- YE Yemen
- 🔘 ZM Zambia
- ZW Zimbabwe
- * Confirmation
 - I confirm I represent my organisation

Frequently asked questions

ec_rtd_cv-manifesto-faq.pdf

I have read the above privacy statement and:

- I agree with the specific privacy statement
- I agree that the name of my organisations is published on the European Commission's website

Data privacy statement

ec_rtd_privacy-statement_consultations_research-manifesto.pdf

Contact

RTD-VALORISATION-POLICIES-IPR@ec.europa.eu